Search

Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.

CMSC Abstracts Search Form (Titles and Authors only)

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2017 SX05 Poster Symptom Management

Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids: A Case Report with 5 Year Follow-up

Aravindhan Veerapandiyan, MD, Amit Chaudhari, PhD and Xue Ming, MD PhD, Rutgers New Jersey Medical School, Newark, NJ

2017 SX06 Poster Symptom Management

Dementia in Patients with MS: Screening, Prevention, Differential Diagnosis, Functional and Safety Assessment, and Interdisciplinary Management

Laura T. Safar, MD, Psychiatry, Harvard Medical School, Boston, MA

2017 SX07 Poster Symptom Management

Retrospective Chart Review of the Amount of IV Fluids Administered and the Infusion Reactions Occurring in Patients Receiving Course One of Lemtrada

Marie Moore, NP, Neurology, Carolinas Healthcare System, Charlotte, NC and Donna Graves, MD, Neurology, Carolinas Healthcare system, Charlotte, NC

2017 SX08 Poster Symptom Management

A Pilot Study of Real Time Longitudinal Fatigue Monitoring in Adults with Relapsing Remitting MS (RRMS)

Pamela Newland, PhD, RN, Nursing, Goldfarb School of Nursing, St. Louis, MO, Brant J. Oliver, PhD, NP, MSN, MPH, MSCN, School of Nursing, MGH Institute of Health Professions, Boston, MA, Boston, MA and Amber Salter, PhD, Biostatistics, Washington University in St. Louis, St. Louis, MO

2017 SX09 Poster Symptom Management

Preliminary Data on the Effects of Fatigue Self-Management Across Ethnically Different Populations

Rebecca Floyd, Ph.D., Rebecca Howell, B.A. and Lara Stepleman, Ph.D., Augusta University, Augusta, GA

2017 SX10 Poster Symptom Management

Prevalence of Patient Self-Reported Sexual Dysfunction in Neuromyelitis Optica Spectrum Disorder

Viviana I Orozco-Leon, MD, S.Richard Dunham, MD and George J Hutton, MD, Neurology, Baylor College of Medicine, Houston, TX

2017 SX11 Poster Symptom Management

Patient-Reported Overactive Bladder in Neuromyelitis Optica Spectrum Disorder

Viviana I Orozco-Leon, MD, S.Richard Dunham, MD and George J Hutton, MD, Neurology, Baylor College of Medicine, Houston, TX

2016 CC01 Platform/Oral Comprehensive Care in MS and Symptom Management

The Profile of a Contemporary Cohort of Participants with Primary Progressive Multiple Sclerosis in the Narcoms Registry

Amber Salter, PhD, Division of Biostatistics, Washington University in St. Louis, St. Louis, MO, Nina Thomas, MPH, Genentech, Inc, South San Francisco, CA, Gary Cutter, PhD, University of Alabama at Birmingham, Birmingham, AL, Ruth Ann Marrie, MD, PhD, University of Manitoba, Winnipeg, MB, Canada and Tuula Tyry, PhD, Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ

2016 CC02 Platform/Oral Comprehensive Care in MS and Symptom Management

Anterior Visual Pathway Measures Are Strongly Associated with Cognitive Function in Multiple Sclerosis

James V Nguyen, BS1, Laura J Balcer, MD, MSCE2, Elliot M Frohman, MD, PhD3, Alissa M Rothman, BS1, Peter A Calabresi, MD1 and Shiv Saidha, MBBCh1, (1)Neurology, Johns Hopkins University, Baltimore, MD, (2)Neurology, New York University Langone Medical Center, New York, NY, (3)Neurology and Ophthamology, University of Texas Southwestern Medical Center, Dallas, TX

2016 CC03 Platform/Oral Comprehensive Care in MS and Symptom Management

Functional Home Evaluation: Missing Pieces in Treatment and Transition Process

Bonnie Schaude, M.A. CCC/SLP, Shepherd Center, Atlanta, GA and Julia P Huerbin, OTR/L, MSCS, MS, Shepherd Center, atlanta, GA

2016 CC04 Platform/Oral Comprehensive Care in MS and Symptom Management

The Interactive, Fatigue Self-Management Resource: The Road from Development to Testing to Hope for a Potential New Fatigue Management Tool

Karen VL Turpin, PhD Candidate, MSc, BScN1, Nadine Akbar, PhD2, Julie Petrin, PhD Student3, Penelope Smyth, MD, FRCPC4 and Marcia Finlayson, PhD, OT Reg (Ont), OTR3, (1)School of Public Health, University of Alberta, Edmonton, AB, Canada, (2)Neuroscience and Neuropsychology Laboratory (NNL), Kessler Foundation, West Orange, NJ, (3)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (4)Division of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada

2016 CC05 Platform/Oral Comprehensive Care in MS and Symptom Management

Multiple Sclerosis at Home Access (MAHA): Care into Communitiy

Kathleen M Healey, ARNP, PhD, NEUROLOGICAL SCIENCES, UNIVERSITY OF NEBRASKA MEDICAL CENTER, OMAHA, NE

2016 CC06 Platform/Oral Comprehensive Care in MS and Symptom Management

Optimizing Multiple Sclerosis Health Care: Health Care Priorities of Americans with Multiple Sclerosis

Malachy Bishop, Ph.D1, Phillip D Rumrill, Ph.D2, Chung-yi Chiu, PhD3, Bradley McDaniels, MRC1 and Byung-Jin Kim, MS1, (1)EDSRC, University of Kentucky, Lexington, KY, (2)Center for Disability Studies, Kent State University, Kent, OH, (3)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL

2016 CC07 Platform/Oral Comprehensive Care in MS and Symptom Management

A Short Film Highlighting MS in Hispanic Lives: Fostering Cultural Sensitivity

Ozioma Obiwuru, MS1, Melanie D’Andrea, MFA2, Lihua Liu, PhD3, Sarah Joseph, MS1, Ana Palomeque, BS1, Leslie Tarlow, NP, MSN1, Bryce Morgan, BA2 and Lilyana Amezcua, MD, MS1, (1)Neurology, University of Southern California, Los Angeles, CA, (2)University of Southern California, Los Angeles, CA, (3)Department of Preventative Medicine, Division of Biostatistics, University of Southern California, Los Angeles, CA

2016 CC08 Platform/Oral Comprehensive Care in MS and Symptom Management

Prevalence of Dysphagia in Multiple Sclerosis and Correlation with Disability

Rola Mahmoud, MD1, George J Hutton, MD1, Kenneth W Altman, MD PhD2, Felicia Carter, MA, CCC-SLP2 and S.Richard Dunham, MD1, (1)Neurology, Baylor College of Medicine, Houston, TX, (2)Otolaryngology-Head & Neck Surgery, Baylor College of Medicine, Houston, TX

2016 CG01 Platform/Oral Psychosocial: Cognition, Depression

Depression, Fatigue, Declines in Cognitive Function, and Uncertainty on Quality of Life Outcomes in Women with Multiple Sclerosis

Cheri L Roseberry, PhD, RN, College of Nursing, University of Arizona, Phoenix, AZ

2016 CG02 Platform/Oral Psychosocial: Cognition, Depression

Sexual Dysfunction and Its Correlation to Depression and Bladder Dysfunction in Hispanics with Multiple Sclerosis

Eduardo R Estades, MD1, Angel Chinea, MD2, Yatzka G Hernandez Silvestrini, MD1, Ivonne Vicente, MD2, Cristina Rubi, BS2 and Carlos Rios, PhD2, (1)Research/Clinic, San Juan MS Center, Guaynabo, PR, (2)San Juan Multiple Sclerosis Center, Guaynabo, PR

2016 CG03 Platform/Oral Psychosocial: Cognition, Depression

Loneliness in Multiple Sclerosis: Putative Antecedents and Manifestations

Julia M Balto, BSc1, Lara A Pilutti, PhD1 and Robert W Motl, PhD2, (1)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, (2)Department of Kinesiology and Community Health, University of Illinois at Urbana Champaign, Urbana, IL

2016 CG04 Platform/Oral Psychosocial: Cognition, Depression

Neuropsychiatric Disorders in Multiple Sclerosis: Assessment and Management

Laura T. Safar, MD, Psychiatry, Harvard Medical School, Boston, MA

2016 CG05 Platform/Oral Psychosocial: Cognition, Depression

Fatigue Measured Using the Neurological Fatigue Index Is Associated with Poor Sleep Quality and Inattentiveness in People with Multiple Sclerosis

Mayis Al dughmi, PT, Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, KS

2016 CG06 Platform/Oral Psychosocial: Cognition, Depression

Sensory Processing, Fatigue and Quality of Life for Adults with Multiple Sclerosis

Melissa A Colbeck, OT Reg. (MB), Occupational Therapy, Health Sciences Centre, Winnipeg, MB, Canada

2016 DX01 Platform/Oral Disease Management, Imaging, and Therapeutics

Patients of African Descent with Active RRMS Demonstrate Clinical and Radiologic Benefits with Alemtuzumab over 5 Years

Annette Okai, MD1, Keith R Edwards, MD2, Brian Steingo, MD3, David H Margolin, MD, PhD4, Sourav Santra, PhD4 and Mitzi J. Williams, MD5, (1)Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, (2)Multiple Sclerosis Center of Northeastern New York, Latham, NY, (3)Fort Lauderdale Multiple Sclerosis Center, Pompano Beach, FL, (4)Genzyme, a Sanofi company, Cambridge, MA, (5)Multiple Sclerosis Center of Atlanta, Atlanta, GA

2016 DX02 Platform/Oral Disease Management, Imaging, and Therapeutics

Patients with Active RRMS and Inadequate Response to Therapy at Baseline Show Durable Disability Improvement over 5 Years with Alemtuzumab: Care-MS II

Christopher LaGanke, MD1, Aaron Boster, MD2, Samuel F. Hunter, MD, PhD3, David H Margolin, MD, PhD4, Karthinathan Thangavelu, PhD4 and Eva Havrdova, MD, PhD5, (1)North Central Neurology Associates, Cullman, AL, (2)OhioHealth Neurological Physicians, Columbus, OH, (3)Advanced Neurosciences Institute, Franklin, TN, (4)Genzyme, a Sanofi company, Cambridge, MA, (5)Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

2016 DX03 Platform/Oral Disease Management, Imaging, and Therapeutics

Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with MS Using a Composite Measure of Disability

J Theodore Phillips, MD, PhD, FAAN1, Amit Bar-Or, MD, FRCPC2, Ralf Gold, MD3, Gavin Giovannoni, MBBCh, PhD4, Robert J Fox, MD, FAAN5, James Potts, PhD6, Teesta Soman, MD, MBA6 and Jing L Marantz, MD, PhD6, (1)Multiple Sclerosis Program, Baylor Institute for Immunology Research, Dallas, TX, (2)Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, (3)Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany, (4)Queen Mary University of London, Blizard Institute, London, United Kingdom of Great Britain and Northern Ireland, (5)Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, (6)Biogen, Cambridge, MA

2016 DX04 Platform/Oral Disease Management, Imaging, and Therapeutics

Natalizumab in Anti-JC Virus Seronegative Patients with Early Relapsing-Remitting Multiple Sclerosis: Interim Results from the STRIVE Study

Jai Perumal, MD1, Roumen Balabanov, MD2, Mary-Jean Fanelli, MD3, Christophe Hotermans, MD3, Allie McGinty, BA3, Qunming Dong, MD3, Laura J Balcer, MD, MSCE4, Steven Galetta, MD5, Jeffrey B English, MD6, Robert J Fox, MD, FAAN7, Lily Lee, MD3 and Denise Campagnolo, MD3, (1)Judith Jaffe Multiple Sclerosis Center, New York, NY, (2)Rush University Multiple Sclerosis Center, Chicago, IL, (3)Biogen, Cambridge, MA, (4)Neurology, New York University Langone Medical Center, New York, NY, (5)New York University Langone Medical Center, New York, NY, (6)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (7)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH

2016 DX05 Platform/Oral Disease Management, Imaging, and Therapeutics

Five-Year Outcomes of Halt-MS: High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Relapsing-Remitting Multiple Sclerosis

Richard A Nash, MD1, George J Hutton, MD2, Michael K Racke, MD3, Uday Popat, MD4, Steven M Devine, MD3, George E Georges, MD5,6, Linda M Griffith, MD PhD7, Paolo A Muraro, MD8, Harry Openshaw, MD9, Peter Sayre, MD10,11, Olaf Stuve, MD12, Douglas L Arnold, MD13, Kaitlyn C McConville, MS14, Annette Wundes, MD15, George H Kraft, MD15 and James D Bowen, MD16, (1)Colorado Blood Cancer Institute, Denver, CO, (2)Baylor College of Medicine, Houston, TX, (3)The Ohio State University Wexner Medical Center, Columbus, OH, (4)MD Anderson Cancer Center, Houston, TX, (5)Fred Hutchinson Cancer Research Center, Seattle, WA, (6)University of Washington, Seattle, WA, (7)National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, (8)Imperial College, London, United Kingdom, (9)City of Hope National Medical Center, Duarte, CA, (10)Immune Tolerance Network, San Francisco, CA, (11)University of California San Francisco, San Francisco, CA, (12)University of Texas Southwestern Medical Center at Dallas, Dallas, TX, (13)McGill University, Montreal, QC, Canada, (14)Rho Federal Systems Division, Inc., Chapel Hill, NC, (15)Rehabilitation Medicine, University of Washington, Seattle, WA, (16)Swedish Medical Center, Seattle, WA

2016 DX06 Platform/Oral Disease Management, Imaging, and Therapeutics

Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 Gadolinium-Enhancing Lesions at Baseline in a Phase III, Placebo-Controlled Trial

Jerry Wolinsky, MD1, Douglas L Arnold, MD2,3, Amit Bar-Or, MD, FRCPC2, Jérôme de Seze, MD, PhD4, Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath5, Bernhard Hemmer, MD6,7, Kottil Rammohan, MD8, Peter Chin, MD9, Paulo Fontoura, MD, PhD10, Hideki Garren, MD, PhD10, Donna Masterman, MD9, Annette Sauter, MD10 and Xavier Montalban, MD, PhD11, (1)University of Texas Health Science Center at Houston, Houston, TX, (2)McGill University, Montreal, QC, Canada, (3)NeuroRx Research, Montreal, QC, Canada, (4)University Hospital of Strasbourg, Strasbourg, France, (5)Queen Mary University of London, London, United Kingdom of Great Britain and Northern Ireland, (6)Technische Universität München, Munich, Germany, (7)Munich Cluster for Systems Neurology (SyNergy), Munich, Germany, (8)University of Miami, Miami, FL, (9)Genentech, Inc., South San Francisco, CA, (10)F. Hoffmann-La Roche Ltd., Basel, Switzerland, (11)Hospital Vall d’Hebron University, Barcelona, Spain

2016 DX07 Platform/Oral Disease Management, Imaging, and Therapeutics

3H-1, 2-Dithiole-3-Thione As a Novel Therapeutic Agent for the Treatment of Experimental Autoimmune Encephalomyelitis

Ping-Chang Kuo, Ph.D.1, Dennis A Brown, Ph.D.2, Barbara A Scofield, B.S.1, I-Chen Yu, Ph.D.3, Fen-Lei Chang, M.D., Ph.D.4 and Jui-Hung Yen, Ph.D.1, (1)Department of Microbiology and Immunology, Indiana University School of Medicine, Fort Wayne, IN, (2)Department of Pharmaceutical Sciences, Manchester University College of Pharmacy, Fort Wayne, IN, (3)Department of Anatomy and Cell Biology, Indiana University School of Medicine, Fort Wayne, IN, (4)Department of Neurology, Indiana University School of Medicine, Fort Wayne, IN

2016 DX08 Platform/Oral Disease Management, Imaging, and Therapeutics

The Effect of Fingolimod on Four Measures of Disease Activity in Patients with Relapsing–Remitting Multiple Sclerosis: A Meta-Analysis of the Phase 3 Freedoms Trials

Pavle Repovic, MD, PhD1, Göril Karlsson, PhD2, Martin Merschhemke, MD2 and Dieter A Häring, PhD2, (1)Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, (2)Novartis Pharma AG, Basel, Switzerland

2016 RH01 Platform/Oral Rehabilitation Interventions

Understanding Engagement Decisions to Maximize Gait and Balance: Persons’ with Multiple Sclerosis and Physical Therapists’ Perspectives

Elissa C Held Bradford, PT, PhD, NCS, MSCS1,2, Andrea White Gorman, PhD, RD, LPC2, Joanne M Wagner, PT, PhD1 and Marcia Finlayson, PhD, OT Reg (Ont), OTR3, (1)Department of Physical Therapy and Athletic Training, Saint Louis University, St. Louis, MO, (2)Rocky Mountain University of Health Professions, Provo, UT, (3)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada

2016 RH02 Platform/Oral Rehabilitation Interventions

A Qualitative Study of a Home-Based DVD Exercise Intervention in Older Adults with Multiple Sclerosis

Elizabeth A Hubbard, MSc1, Yvonne C Learmonth, PhD1, Dominique L Kinnett-Hopkins, BS1, Thomas Wojcicki, PhD2, Sarah Roberts, BS1, Jason Fanning, MS1, Edward McAuley, PhD1 and Robert W Motl, PhD1, (1)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, (2)Exercise Science, Bellarmine University, Louisville, KY

2016 RH03 Platform/Oral Rehabilitation Interventions

Associations Between UE Body Functions and Clinical Characteristics Among Persons with Multiple Sclerosis

Elizabeth W. Triche, PhD1,2, Kayla M. Olson, MA1, Jennifer A. Ruiz, DPT1 and Albert C. Lo, MD, PhD1, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, (2)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT

2016 RH04 Platform/Oral Rehabilitation Interventions

Application of a Clinical Practice Guideline for Persons with Multiple Sclerosis in a Multi-Setting, Multi-Discipline Rehabilitation Facility

Kelli Doern, PT, DPT, NCS, MSCS and Morgan Eppes, PT, DPT, Sheltering Arms Physical Rehabilitation Centers, Richmond, VA

2016 RH05 Platform/Oral Rehabilitation Interventions

The Benefit of Tai Chi on Balance and Gait in People with Multiple Sclerosis

Linda A Csiza, PT, DSc, NCS, Physical Therapy, Texas Woman’s University, Dallas, TX

2016 RH06 Platform/Oral Rehabilitation Interventions

Rate of Production of Individual Phonemes of the Diadochokinetic Rate in Pwms Both with and without Complaints of Speech Production or Swallowing Difficulty

Lori A Kostich, M.S. CCC-SLP, MSCS, Mount Sinai Rehabilitation Hospital, Hartford, CT

2016 RH07 Platform/Oral Rehabilitation Interventions

Assistive Device Training Results in Improved Functional Mobility and Reduced Thalamo-Cortical Connectivity in People with MS

Brett W. Fling, PhD1, Douglas Martini, PhD1, Andrea Hildebrand, BA1,2, Eline Zeeboer, MSc, PT1 and Michelle H Cameron, MD, PT1,2, (1)Neurology, Oregon Health & Science University, Portland, OR, (2)Neurology, Portland VA Medical Center, Portland, OR

2016 RH08 Platform/Oral Rehabilitation Interventions

Physical Functioning Among Older Adults with MS: Evidence Based on an Objective Outcome

Robert W Motl, PhD1, Julia M Balto, BSc1, Manuel E Hernandez, PhD1 and Brian M Sandroff, PhD2, (1)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, (2)Kessler Foundation, West Orange, NJ

2016 CC09 Poster Comprehensive Clinical Care – A Team Approach

Women in Neurology: Lessons Learned and Lessons Still Learning

Amy Sullivan, Psy.D.1, Mary R Rensel, MD1, Carrie M Hersh, DO, MS2 and Catherine Boyle, Manager3, (1)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, (2)Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, (3)Women’s Professional Staff Association, Cleveland Clinic, Cleveland, OH

2016 CC10 Poster Comprehensive Clinical Care – A Team Approach

Optical Coherence Tomography (OCT) Measures Are Associated with Patient Self-Reported Vision Scores in Persons with Multiple Sclerosis (MS)

Benjamin I Richter, BA1, Rivka R Green, BA2, Jillian Mohn, BS1, Parth B Saraiya, HSD1 and Krupa S Pandey, MD1, (1)Multiple Sclerosis Comprehensive Care Center, Barnabas Health, Livingston, NJ, (2)MS Comprehensive Care Center, NYU Langone, New York, NY

2016 CC11 Poster Comprehensive Clinical Care – A Team Approach

Specialty Pharmacy Leveraging Disease Management and Technology to Help Multiple Sclerosis Patients Adhere to Treatment Plan

Bincy Varghese, PharmD, St. John University School of Pharmacy, New York, NY